A novel indoor localization scheme based on fingerprinting technique And CDMA signals

International audience—In this paper, we propose a novel acoustic local-ization system based on fingerprinting technique. It deploys the Time Of Arrival of CDMA signals emitted by speakers to locate a microphone. The system is inspired from our earlier proposed scheme [1] which deploys the lateration method. Here, we adopt the fingerprinting technique since it is more applicable to indoor environments. The position estimation is accomplished through nonparametric kernel regression. Performance are evaluated by experiments, performed in a hall of interns in National School of Engineers of Le Mans. Results have shown that our proposed scheme provides an accuracy of 8.5 cm within 80% precision

Multi-resolution localization method based on time reversal and simulated annealing algorithm

International audience—In this paper, we propose a novel acoustic indoor localization system that is based on time reversal. The system estimates the target position with different precision. First, it uses a low frequency signal in order to localize the source in the whole area within coarse precision. Then, it switches to high frequency signal to estimate the target location in a reduced area within a fine precision. The system performance have been evaluated by simulations and by experiments conducted in a practical training room in the National School of Engineers of Le Mans. Results have shown that the system has subcentimeter accuracy

Genomic Instability and Pro-Tumoral Inflammation are associated with Primary Resistance to Anti-PD1 + Anti-Angiogenesis in Malignant Pleural Mesothelioma

International audienceCancer immunotherapy combinations have recently shown to improve the overall survival of advanced mesotheliomas especially for patients responding to those treatments. We aimed to characterize the biological correlates of malignant pleural mesotheliomas primary resistance to immunotherapy and anti-angiogenics by testing the combination of pembrolizumab, an anti-PD-1 antibody, and nintedanib, a pan anti-angiogenic tyrosine kinase inhibitor (TKI), in the multi-center PEMBIB trial (NCT02856425). Thirty patients with advanced malignant pleural mesothelioma were treated and explored. Unexpectedly, we found that refractory patients were actively recruiting CD3+CD8+ cytotoxic T-cells in their tumors through CXCL9 tumor release upon treatment. However, these patients displayed high levels of somatic copy number alterations in their tumors that correlated with high blood and tumor levels of IL-6 and CXCL8. Those pro-inflammatory cytokines resulted in higher tumor secretion of VEGF and tumor enrichment in regulatory T-cells. Advanced mesothelioma should further benefit from stratified combination therapies adapted to their tumor biology